MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-15-2023
CTI BioPharma Corp. DSO Ratio 2011-2026 | CTIC
Annual DSO Ratio CTI BioPharma Corp.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 52.1 | - | - | - | 190 | 18.6 | 51.9 | 6.39 | 12.2 | 2.47 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 190 | 2.47 | 47.6 |
Quarterly DSO Ratio CTI BioPharma Corp.
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 72.5 | - | 46.9 | 39.2 | 48.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.02 | 18.2 | 17.7 | 0.99 | 23.1 | 3.78 | 7.78 | 4.69 | 0.83 | 2.27 | 26.7 | 23.4 | 38.4 | 10.3 | 4.64 | 137 | 72.6 | 0.65 | 59.2 | 70.1 | 9.52 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 137 | 0.02 | 29.5 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Adagene
ADAG
|
53.8 | $ 1.65 | 6.11 % | $ 92.9 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 3.43 | -2.69 % | $ 8.25 B |  Australia |
 |
Biogen
BIIB
|
57.9 | $ 177.93 | -4.15 % | $ 25.9 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 65.89 | -0.06 % | $ 8.81 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
103 | - | -7.31 % | $ 87 M | USA |
 |
Ascendis Pharma A/S
ASND
|
132 | $ 214.55 | 2.77 % | $ 5 B |  Danmark |
 |
Bristol-Myers Squibb Company
BMY
|
81.9 | $ 55.84 | 0.13 % | $ 113 B | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M |  Canada |
 |
Caladrius Biosciences
CLBS
|
164 | - | -16.75 % | $ 25.8 M | USA |
 |
Clearside Biomedical
CLSD
|
61.7 | - | - | $ 25.3 M | USA |
 |
Chimerix
CMRX
|
588 | - | - | $ 756 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 4.18 | -1.65 % | $ 9.1 B |  Israel |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Catalyst Biosciences
CBIO
|
3.24 | $ 11.09 | 1.0 % | $ 730 M | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
Coherus BioSciences
CHRS
|
263 | $ 1.69 | 2.12 % | $ 159 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
62.6 | $ 28.99 | -1.39 % | $ 1.4 B | USA |
 |
Celldex Therapeutics
CLDX
|
86.5 | $ 25.71 | 0.16 % | $ 1.66 M | USA |
 |
Cellectis S.A.
CLLS
|
94.5 | $ 4.24 | -0.47 % | $ 116 M |  France |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | USA |